India's Glenmark Pharma gains after cancer drug launch
25/06/2025 10:09
** Shares of Glenmark Pharmaceuticals GLEN.NS rises 2.6% to 1,729 rupees, their highest since November 2024 ** Pharma co launches Tevimbra — an immunotherapy drug used to treat cancer — marking its foray into immune-oncology in India ** Avg rating on stock is "buy;" median PT is 1,695 rupees - data compiled by LSEG ** Stock up 6.3% YTD (Reporting by Aleef Jahan in Bengaluru) ((aleefjahan.cs@thomsonreuters.com))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter